Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs

Back to Jobs

FDA’s review confirms use of Negative Binomial m odel for analysis of primary endpoint in   ongoing OTIVIDEX Phase 3 trial in   Ménière’s disease ; results still expected in first quarter of 2021 Company finalizing d esign of Phase 2 trial for OTO-313 in tinnitus and expects to start study in the

Apply Now